Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR loc

Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

AZUR-1 data showing clinically significant proportion of participants with no detectable signs of cancer one year or more after treatment